Recent Updates — INCY
Incyte reported third-quarter total revenue of $1.56 billion, a 14% increase year-over-year, driven by a 14% rise in total net sales to $1.32 billion. Jakafi net sales grew 4% to $827 million, while Opzelura and Hematology/Oncology portfolios surged 36% and 38%, respectively. The company raised its full-year 2026 net sales guidance to $5.21–$5.30 billion from the previous range of $5.13–$5.26 billion, citing strong commercial performance. Incyte operates in the biopharmaceutical industry, developing and commercializing medicines for hematology, oncology, and inflammation.
Incyte Corporation reported second quarter 2026 financial results with total revenue of $1.67 billion and total net sales of $1.49 billion, representing increases of 38% and 40% respectively compared to the prior year period. Net sales growth was significantly impacted by a one-time, non-cash benefit of $246 million from the reversal of accrual balances related to a CMS settlement regarding Opzelura. Excluding this benefit, total net sales grew 17%. Jakafi net sales increased 7% to $817 million, while Opzelura net sales surged 173% to $450 million. The company raised its full-year 2026 total net sales guidance to $5.13–$5.26 billion and operating expense guidance to $4.915–$4.995 billion, reflecting the CMS agreement impact and the acquisition of Vega Therapeutics for $1.25 billion. Incyte operates in the biopharmaceutical industry, developing and commercializing medicines for hematology, oncology, and inflammation.
Incyte Corporation completed its acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics LLC. The company is a biotechnology company that develops and commercializes commercial-stage and commercial-stage ready products for oncology and inflammation.
Incyte Corporation reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation regarding Medicaid rebate rules for Opzelura (ruxolitinib) cream. The settlement prevents CMS from treating Opzelura as a line extension of Jakafi, resulting in a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026. Incyte Corporation is a biotechnology company that develops and commercializes therapeutic products.
Incyte Corporation held its Annual Meeting of Shareholders on June 8, 2026, where shareholders elected eight directors, approved non-binding advisory compensation for named executive officers, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Incyte Corporation is a biotechnology company that develops and commercializes therapeutic products.